SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) February 23, 1998
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On February 23, 1998, Biocontrol Technology, Inc.
(NASDAQ:BICO) announced that it has received a Letter of Intent
from Mr. Nasser Daen Al Shamsi of Abu Dhabi, United Arab
Emirates, stating the intent to enter into a joint venture for
the purpose of building and operating a cancer treatment center
to untilize Biocontrol's ThermoChem System.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information
and Exhibits.
(a) Financial Statements and Businesses Acquired - Not
Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act
of 1934, the Registrant has duly caused this Report to be signed
on its behalf by the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
CEO
DATED: February 23, 1998
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL RECEIVES LETTER OF INTENT FOR THERMOCHEM CANCER
TREATMENT CENTER
Pittsburgh, PA - February 23, 1998 - Biocontrol Technology,
Inc. (Nasdaq:BICO)
announced today that it has received a Letter of Intent from Mr.
Nasser Daen Al Shamsi of Abu Dhabi, United Arab Emirates (UAE),
stating the intent to enter into a joint venture for the purpose
of building and operating a cancer treatment center to utilize
Biocontrol's ThermoChem System.
Mr. Nasser, a very prominent business leader of the UAE,
intends to provide the land and building for such a venture, and
Biocontrol is to supply the ThermoChem System and the expertise
necessary to use the system in the treatment of various types of
cancer. Mr. Mazin Agha, Biocontrol's exclusive representative
for the UAE, arranged the joint venture and will continue to
assist with the necessary details.
The ThermoChem System delivers perfusion induced systemic
hyperthermia, a form of extracorporeal therapy in which the core
body temperature is raised to 42.5 degrees C for one hour or more
by direct extracorporeal heating of the blood. During treatment,
the ThermoChem System balances critical blood chemistries on a
real time basis. Heat has already been proven to have a
detrimental effect on tumor cells and can also increase the
effectiveness of radiation, chemotherapy, and biological therapy.
Through Biocontrol subsidiary, IDT, Inc., the ThermoChem
System is currently in a metastatic non-small cell lung cancer
study with the University of Texas Medical Branch at Galveston,
as well as preclinical studies with The University of Texas M. D.
Anderson Cancer Center for Phase I/II Trials of a
thermochemotherapy hemi-perfusion of patients with pelvic or
lower extremity cancer.
To facilitate the introduction of the ThermoChem System into
the UAE, Biocontrol will soon open an office in Abu Dhabi, UAE,
which will also be helpful in the introduction of other
Biocontrol products such as the Diasensor 1000 noninvasive
glucose sensor and the PRP oil spill clean up product. A
Diasensor was recently sent to Abu Dhabi to be calibrated, and as
needed, additional sensors will be shipped.
The details of opening the Abu Dhabi office will be handled
by Mr. Stan Cottrell, who has been working in the UAE for
Biocontrol during the last several months and has been
instrumental in establishing the necessary high level contacts.
Biocontrol Technology, Inc. has its corporate offices in
Pittsburgh, PA and is involved in the development and manufacture
of biomedical devices and environmental products.
